The Department of Disease Control reports the weekly COVID-19 situation, indicating that data for the 46th week between 12-18 October 2023 had 390 new patients hospitalized, a daily average of 56 cases per day, accumulated sickness since the beginning of 2023. at 35,188 cases, while intensive care patients increased from last week. It was reported that there were 83 cases of pneumonia and 40 cases of intubated patients. The death toll remains the same, 1 person per week. The cumulative number of deaths since the beginning of 2023 is 821.
COVID-19 is stable this week in Thailand – Genome Center reveals that double mutations of COVID have been found – it has reversed all over the world.
Update COVID Deltacron XBC – Expected in 2024, the world will see “JN.1” as the main strain.
For the number of people vaccinated against COVID-19 There have been no reports of additional people receiving the vaccine. At present, a cumulative total of 144,951,341 doses of vaccine have been administered, divided into 57,233,919 doses of the 1st vaccine, accounting for 82.28%, 53,730,348 doses of the 2nd dose, accounting for 77.25%, and from the 3rd dose onwards, 33,987,074 doses (updated date on 26 May 2023)
Medical Genome Center Faculty of Medicine Ramathibodi Hospital posted on Facebook Center for Medical Genomics Regarding progress in the efficiency of treating people infected with COVID-19 belonging to the fragile group
It stated that the Thai medical team published research results on the effectiveness of treating people infected with COVID-19. who are in the “vulnerable group” with plasma from the blood of people who have recovered from COVID-19 delta strain (Covid-19 Convalescent Plasma: CCP) combined with “favipiravir” compared to treatment With the ready-made antibody “Sotrovimab” it was found to be effective in treating people infected with COVID-19. Omicron strain BA.1/BA.2 as well “CCP+Favipiravir” is no different from the ready-made antibody treatment “sotrovimab”. But CCP and favipiravir are much cheaper to produce than ready-made antibodies and Thailand can produce them itself.
This may be another option for treating patients infected with SARS-CoV-2 in Thailand and around the world, especially in the early stages of the outbreak when the production of vaccines, drugs, and ready-made antibodies is not yet ready. or COVID-19 patients That person did not respond to any treatment.
From lessons learned from treating COVID-19 In Thailand, it was found that during the COVID outbreak the Delta strain was very severe. Most patients during that time were infected and had severe symptoms. Most often have never received the vaccine or have not received 2 doses or less than 2 doses within 14 days before becoming infected and are those who have difficulty accessing medicine. Didn’t receive Farvipiravia within 48 hours. Many patients in serious condition were hospitalized and lived for less than 7 days and many died.
To reduce people’s deaths from COVID-19 During that time, medical teams from many institutions, namely Prachathipat (Community) Hospital, Pathum Thani Province, Chulabhorn Hospital, Chulabhorn Royal College, and the Center of Excellence in Clinical Virology, Department of Pediatrics Faculty of Medicine Chulalongkorn University Bangkok has brought Covid-19 Convalescent Plasma (CCP) or plasma from the blood of people who have recovered from Covid-19. The Delta strain with a high concentration of antibodies to SARS-CoV-2 (more than 1:320) is produced by the Thai Red Cross. Used for the first time with “Patients in the vulnerable group” which appeared to be effective This is a step forward from the US Food and Drug Administration (FDA) originally approving the use of CCP with a high concentration of SARS-CoV-2 antibodies only to treat patients infected with COVID-19. who are immunocompromised or have been treated with immunosuppressive drugs Both for patients treated in the hospital and patients outside the hospital. only
Fake news! Confirming that the government has not yet ordered the suspension of the New Year after rumors of the COVID Deltacron XBC outbreak spread.
In 2022, the work was published in the peer-reviewed medical journal “Annals of Clinical Microbiology and Antimicrobials.” or a group that is not the producer of that work Compare with the criteria or standards that have been set. and who will be able to inspect the work of others It is necessary to have the same expertise as the producer of the piece. or more specialized)
Later, on November 17, 2023, the same research team published their research results in the medical journal Microbiology Spectrum. The study is a randomized controlled trial examining the efficacy of treatment with plasma from people who have recovered from the Delta strain of COVID-19 with a high neutralizing titer. ) together with favipiravir Compared with treatment with the ready-made antibody drug “Sotrovimab”, it was found that the efficacy of treatment with CCP (produced from people infected with the Delta strain) combined with favipiravir was found. not inferior to “sotrovimab (Sotrovimab)” which is a ready-made antibody. To treat COVID-19 strains BA.1 and BA.2 over a period of 14 and 28 days, a total of 136 volunteers participated in the trial, 68 of whom received CCP+favipiravir. and 68 received sotrovimab. There were no significant differences between the two treatment groups in emergency admissions. oxygenation and death
Note: Using ready-made antibody drugs (Monoclonal Antibodies) to treat COVID-19 is effective in reducing the amount of virus in the bloodstream and inhibiting infection of the body. Including reducing the time spent in hospital. and reduce the risk of death Ready-made antibody drugs are specific to each strain of COVID (narrow spectrum). For example, some ready-made antibody drugs are good at treating OMICRON strains BA.1/BA.2 but are very ineffective in treating people with Infected with Omicron strain XBB.1.5 etc.
Most recently, internists from Prachathipat Hospital have collaborated with the Medical Genome Center at Ramathibodi Hospital (to test COVID strains) to treat COVID patients with BA.4 and BA.5 strains with CCP from people who were previously infected. and recovery from the Delta strain was found to be effective as well This research work is currently being prepared for publication in an academic journal.
Lessons learned from the use of CCP in Thailand produced from people infected with the original strain of Covid (Delta) by the Thai Red Cross may be applicable to the outbreak of the new strain of Covid at that time, which is Omicron BA. 1/BA.2 while BA.4/BA.5 are in the process of being published. It shows that the CCP has the power to capture and destroy the COVID-19 virus. A wider variety of species (broad spectrum) than ready-made antibodies It should be able to be used against new strains of COVID that may occur in the future. Especially in the early stages of the outbreak, the production of vaccines, medicines, and ready-made antibodies was not yet ready. or COVID-19 patients The person did not respond to any treatment. This will be another option for treating patients infected with SARS-CoV-2 in Thailand and around the world. And CCP treatment is generally safe and has few side effects.
Doctor reveals he is infected with COVID19 Along with the flu there is a possibility
Why is “allergy” more severe during the winter? Risk of asthma-sinusitis
2023-11-20 03:50:00
#COVID19 #increasing #illness #week #Genome #Center #reveals #research #drugs #treat #vulnerable #groups #PPTVHD36
